Across TCGA pan-cancer cohorts, MIR920 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of MIR920’s most consistent transcriptional readouts.
The strongest signal is observed in lung adenocarcinoma (LUAD), where MIR920 RNA is repressed in tumor relative to normal tissue. In most cancer types MIR920 is over-expressed in tumor, although a few such as LUAD and THCA show the opposite, repressed pattern.
LUAD and THCA are the cancer types where MIR920 tumor–normal differential expression is most reproducible.